Table 3.

Raw results: relative efficacy vs placebo on ACR20, ACR50, and ACR70 response criteria.

Active TreatmentStudyACR20 OR (95% CI)ACR50 OR (95% CI)ACR70 OR (95% CI)
InfliximabMaini213.89 (1.99–7.59)7.22 (2.37–21.99)
Schiff222.04 (1.25–3.32)2.35 (1.33–4.12)3.20 (1.53–6.71)
Westhovens233.92 (2.85–5.39)4.40 (2.88–6.71)3.34 (1.86–6.00)
Zhang243.29 (1.72–6.29)2.26 (1.19–4.29)1.84 (0.84–4.05)
EtanerceptWeinblatt256.79 (2.53–18.21)18.53 (2.35–145.51)
Combe267.42 (3.46–15.89)6.78 (2.79–16.50)16.12 (2.12–122.82)
AdalimumabWeinblatt2712.05 (5.04–28.79)14.06 (5.00–39.51)7.22 (2.00–25.97)
Keystone284.12 (2.72–6.24)6.12 (3.54–10.60)10.23 (3.96–26.42)
Kim292.78 (1.36–5.69)4.54 (1.92–10.73)3.18 (1.07–9.45)
Furst302.09 (1.52–2.87)3.19 (2.09–4.87)4.96 (2.53–9.75)
GolimumabKeystone313.82 (2.16–6.74)3.76 (1.95–7.26)4.56 (1.82–11.45)
Kay322.54 (0.97–6.65)9.75 (2.00–47.50)
Certolizumab pegolKeystone59.08 (5.78–14.28)7.25 (4.12–12.75)8.74 (3.75–20.41)
Smolen614.16 (7.26–27.62)14.82 (5.29–41.55)23.74 (3.22–174.93)
AnakinraCohen332.36 (1.55–3.62)2.61 (1.46–4.84)3.14 (1.16–10.06)
TocilizumabGenovese344.66 (3.58–6.07)6.22 (4.31–8.98)8.91 (4.89–16.21)
Smolen353.92 (2.58–5.95)6.47 (3.84–10.90)14.06 (4.95–39.93)
Maini364.13 (1.76–9.66)2.93 (1.28–6.75)3.14 (1.22–8.11)
Kremer373.45 (2.56–4.65)
  • ACR: American College of Rheumatology.